SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 14, 2022 | Series B | €75M | 1 | — | — | Detail |
Oct 13, 2021 | Corporate Round | — | 1 | Intellia Therapeutics | — | Detail |
Oct 21, 2020 | Series A | €44.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Intellia Therapeutics | Yes | Corporate Round |
Retinal Degeneration Fund | — | Series B |
Foundation Fighting Blindness | — | Series A |